Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity

[1]  Jeffrey S. Miller,et al.  Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma , 2020, Blood.

[2]  R. Pierce,et al.  Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma , 2019, Clinical Cancer Research.

[3]  P. Wen,et al.  Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial , 2019, Science Translational Medicine.

[4]  D. Irvine,et al.  Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy , 2019, Science Translational Medicine.

[5]  S. Hadrup,et al.  Lipid Nanoparticles for Delivery of Therapeutic RNA Oligonucleotides. , 2019, Molecular pharmaceutics.

[6]  Tyler E. Wagner,et al.  In vitro evolution of enhanced RNA replicons for immunotherapy , 2019, Scientific Reports.

[7]  M. Merad,et al.  Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination , 2019, Nature Medicine.

[8]  K. Burke,et al.  Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs , 2019, Science Translational Medicine.

[9]  R. Pierce,et al.  Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy , 2018, Gene Therapy.

[10]  Michael E. Lassman,et al.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy , 2017, Cell.

[11]  B. Nelson,et al.  Oncolytic viruses as engineering platforms for combination immunotherapy , 2018, Nature Reviews Cancer.

[12]  T. Chan,et al.  Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for the treatment of glioma , 2018, Cancer Gene Therapy.

[13]  G. Barber,et al.  Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells. , 2018, Cancer cell.

[14]  N. Lemoine,et al.  Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent , 2017, Nature Communications.

[15]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[16]  Michael E. Lassman,et al.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy , 2017, Cell.

[17]  K. Blenman,et al.  UV‐induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model , 2017, Pigment cell & melanoma research.

[18]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[19]  N. Tinari,et al.  Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally , 2017, The Journal of Immunology.

[20]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[21]  Ryan L. Kelly,et al.  Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses , 2016, Nature Medicine.

[22]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[23]  H. Kaufman,et al.  Oncolytic viruses: a new class of immunotherapy drugs , 2016, Nature Reviews Drug Discovery.

[24]  J. Brody,et al.  In situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf , 2015, Molecular oncology.

[25]  David W. McComb,et al.  An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo. , 2015, Nano letters.

[26]  H. Kaufman,et al.  Oncolytic viruses: a new class of immunotherapy drugs , 2015, Nature Reviews Drug Discovery.

[27]  Jianzhu Chen,et al.  Persistent Antigen and Prolonged AKT–mTORC1 Activation Underlie Memory CD8 T Cell Impairment in the Absence of CD4 T Cells , 2015, The Journal of Immunology.

[28]  Troy Guthrie,et al.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[30]  I. Melero,et al.  Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade , 2015, Cancer Immunology Research.

[31]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[32]  B. Shutinoski,et al.  Type-I interferon signaling through ISGF3 complex is required for sustained Rip3 activation and necroptosis in macrophages , 2014, Proceedings of the National Academy of Sciences.

[33]  H. Kohrt,et al.  Intratumoral Immunization: A New Paradigm for Cancer Therapy , 2014, Clinical Cancer Research.

[34]  Shimeng Liu,et al.  Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. , 2014, Nanomedicine.

[35]  M. Jakóbisiak,et al.  Interleukin 12: still a promising candidate for tumor immunotherapy? , 2014, Cancer Immunology, Immunotherapy.

[36]  D. Kirn,et al.  Oncolytic and Immunotherapeutic Vaccinia Induces Antibody-Mediated Complement-Dependent Cancer Cell Lysis in Humans , 2013, Science Translational Medicine.

[37]  M. Hepworth,et al.  TSLP Elicits IL-33–Independent Innate Lymphoid Cell Responses to Promote Skin Inflammation , 2013, Science Translational Medicine.

[38]  F. Sutterwala,et al.  Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome , 2009, Proceedings of the National Academy of Sciences.

[39]  J. Tschopp,et al.  Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors , 2009, Nature Medicine.

[40]  J. Prieto,et al.  Semliki Forest Virus Expressing Interleukin-12 Induces Antiviral and Antitumoral Responses in Woodchucks with Chronic Viral Hepatitis and Hepatocellular Carcinoma , 2009, Journal of Virology.

[41]  Yingqun Wang,et al.  Wnt/Planar cell polarity signaling: A new paradigm for cancer therapy , 2009, Molecular Cancer Therapeutics.

[42]  Richard Heller,et al.  Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[44]  L. Zitvogel,et al.  Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.

[45]  S. Akira,et al.  TLR signaling. , 2006, Current topics in microbiology and immunology.

[46]  S. Akira,et al.  TLR signaling , 2006, Cell Death and Differentiation.

[47]  N. Selzner,et al.  Water induces autocrine stimulation of tumor cell killing through ATP release and P2 receptor binding , 2004, Cell Death and Differentiation.

[48]  M. Looman,et al.  Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  T. Misteli,et al.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2002, Nature.

[50]  D. Coppola,et al.  IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.